Cutting edge microwave imaging device for safe and accurate breast cancer screening

Información del proyecto

MammoWave

Identificador del acuerdo de subvención: 830265

DOI

10.3030/830265

Proyecto cerrado

Fecha de la firma de la CE 10 Octubre 2018

Fecha de inicio 1 Octubre 2018

Fecha de finalización 31 Agosto 2021

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 1 990 163,50

Aportación de la UE

€ 1 393 114,45

Coordinado por

UMBRIA BIOENGINEERING TECNOLOGIES SOCIETA A RESPONSABILITA LIMITATA
Italy

Periodic Reporting for period 3 - MammoWave (Cutting edge microwave imaging device for safe and accurate breast cancer screening)

Período documentado: 2021-04-01 hasta 2021-08-31

Resumen del contexto y de los objetivos generales del proyecto

The MammoWave project addresses the shortcomings and risks associated with mammography. Mammography has been the medical industry’s “gold standard” breast cancer screening tool for nearly four decades. However, a number of adverse effects, including those caused by exposure to x-rays, are now limiting the use of mammography as a mass screening.

Finding a reliable and safer alternative to mammography is key to reduce the burden of breast cancer to society. Breast cancer is the most prevalent form of cancer in women. One in nine women will acquire breast cancer at some point in their life and one in thirty will die from the disease.

The overall objectives of the MammoWave H2020 project are:

1) Development of a interoperable application for MammoWave imaging management
2) Prove MammoWave large scale manufacturability and assembly repeatability
3) Validate MammoWave’s performances in international clinical study
4) Develop international commercial channels

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Throughout the entire, UBT has been working on all the five work packages, with significant results secured:

1) Development and delivery of the suite of software managing the operations of the MammoWave device (WP1)
2) Conversion of the MammoWave’s output into DICOM format for the complete interoperability of the device in every hospital environment (Milestone of this project, WP1)
3) Assembly and successful testing of the first batch of 8 MammoWave units (MammoWave IV generation) (WP2)
4) Ethics committee authorisation from hospitals San Martino (Genova, Italy), Humanitas (Milan, Italy), Hospital Virgen de la Salud (Toledo, Spain) (WP3)
5) Clinical validation performed on 354 patients in 3 clinics, showing positive results of Mammowave (WP3)
6) Publications on prestigious journals such as Scientific Reports (a natureresearch journal) and Biomedical Signal Processing and Control (Elsevier)(WP4)
7) Identification of strong potential commercial partners and significant progress with selected investors (WP4)

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The international clinical study confirmed MammoWave's overall accuracy above 80%. The clinical study was conducted on 354 patients, way above the 250 limit needed to collect statistical significant data for obtaining fast market approval. These results are expected to fast track MammoWave's entry into the EU market. Therefore, the MammoWave H2020 project can have a big impact on the company boosting UBT's growth and commercial success. And, most importantly, on the millions of patients looking for a safer and reliable breast cancer screening alternative.

The team standing behind the newly assembled MammoWave